**Description**

**A COMPOSITION FOR PROMOTING TISSUE RENEWAL**

**Technical Field**

The invention relates to a composition formed for promoting the tissue renewal.

**State of the Art**

Tissue is an ensemble of the cells forming one of the constituents of a body or an organ. In the worn tissue, the impairment and quality degradation in the structure of the tissue and the reduction in the blood circulation are the main factors. The disorders in which this problem is encountered include the problems such as the body pains caused by aging, shoulder pain, shoulder muscle tears, joint wears, disruption in the soft tissues surrounding the joints, tennis and golf elbow, tendinitis, waist and neck problems, the tissues with chronic pain.

As a treatment method, the fibroblast application is performed in the following manner: Local anesthesia is performed on the skin, and then a 4-mm piece is taken from the back of the ear. Then, the location is brought together with a skin adhesive. The skin sample taken is sent to a laboratory for the proliferation of the fibroblasts therein. After a waiting time of 8-10 weeks, the newly formed fibroblasts become ready for use. The growth rate of the cell culture is not the same in every individual. Therefore, the time will vary from one person to another. The second therapy will be performed about one month after the first injection.

According to the state of the art, the invention no. EP1315771B1 with classification “C08J 9/26” entitled “Biologically active material” relates to a heterophasic composition which essentially consists of three immiscible components, A, B and C, and the production method of the same. The component A is some body compatible polymer, the component B is a water soluble or hydrolytically degradable substance which produces cavities or network like porosity after disappearing through solubilization or degradation, and a bioactive substance C which at least component B contains in form of particles as a blend component still exists in the pores or their walls after the degradation or solubilization of the component B. The materials according to the invention are biocompatible, solid in normal temperatures, mechanically processable, and thermally moldable as well as bioactive in the sense that they have the capability to renew different kinds of tissues in the body, on the surface of the living organisms, in the cavities of the body and in the tissue engineering conditions outside the body, and that they can be used in tissue engineering, in tissue regeneration, in healing of damaged or lacking tissues, in tissue guiding when treating deficiencies, in controlled drug release, in the treatment methods of dentistry, in orthopedics and in plastic surgery.

Further, the invention no. PCT/GB2009/051396 entitled “Treatment using reprogrammed mature adult cells” provides a method of treating various diseases, disorders, or conditions in a patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.

As a result, the presence of the need for a composition for promoting the tissue renewal and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to increase the level of igf-1 and epithelial growth factor.

Another object of the invention is to stimulate the BDNF expression.

Another object of the invention is to increase the level of vascular epithelial growth factor.

Another object of the invention is to increase the expression of transforming growth factor type 1.

Another object of the invention is to stimulate the expression of the nerve growth factor.

In order to achieve the aforesaid advantages, the invention is a composition for promoting the tissue renewal, said composition being obtained by the components selected from the group comprising 6-beta-(16,20)-stigmast-6-en-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-en-phenyl-4-one, 11-fluoromethoxy-tricyclopentane, 7-ketoethyl-pentacyclopentane, 4,5-hexamethylhecogenin, trimethyldioscin that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition for promoting the tissue renewal. Said composition increases the level of igf-1 and epithelial growth factor, increases the level of vascular epithelial growth factor, increases the expression of transforming growth factor type 1, stimulates the expression of the nerve growth factor and stimulates the BDNF expression.

The composition according to the invention contains 6-beta-(16,20)-stigmast-6-en-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-en-phenyl-4-one, 11-fluoromethoxy-tricyclopentane, 7-ketoethyl-pentacyclopentane, 4,5-hexamethylhecogenin and trimethyldioscin.

Said composition is obtained by a mixture of the aforesaid components according to the following ratios by weight:

2-10% 6-beta-(16,20)-stigmast-6-en-phenyl-4-one,

8-4% 7-alpha-(17,20)-stigmast-6-en-phenyl-4-one,

20-16% 11-fluoromethoxy-tricyclopentane,

20-25% 7-ketoethyl-pentacyclopentane,

15-20% 4,5-hexamethylhecogenin,

35-25% trimethyldioscin

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for promoting the tissue renewal and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for promoting the tissue renewal, said composition being obtained by the components selected from the group comprising 6-beta-(16,20)-stigmast-6-en-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-en-phenyl-4-one, 11-fluoromethoxy-tricyclopentane, 7-ketoethyl-pentacyclopentane, 4,5-hexamethylhecogenin, trimethyldioscin that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 2-10% by weight 6-beta-(16,20)-stigmast-6-en-phenyl-4-one.
3. A composition according to Claim 1 characterized in that it comprises 8-4% by weight 7-alpha-(17,20)-stigmast-6-en-phenyl-4-one.
4. A composition according to Claim 1 characterized in that it comprises 20-16% by weight 11-fluoromethoxy-tricyclopentane.
5. A composition according to Claim 1 characterized in that it comprises 20-25% by weight 7-ketoethyl-pentacyclopentane.
6. A composition according to Claim 1 characterized in that it comprises 15-20% by weight 4,5-hexamethylhecogenin.
7. A composition according to Claim 1 characterized in that it comprises 35-25% by weight trimethyldioscin.
8. Use of the components according to any one of Claims 1-7 obtained individually or in combinations selected from the group consisting of 6-beta-(16,20)-stigmast-6-en-phenyl-4-one, 7-alpha-(17,20)-stigmast-6-en-phenyl-4-one, 11-fluoromethoxy-tricyclopentane, 7-ketoethyl-pentacyclopentane, 4,5-hexamethylhecogenin, trimethyldioscin for the manufacture of a composition for promoting the tissue renewal.

**ABSTRACT**

**A COMPOSITION FOR PROMOTING TISSUE RENEWAL**

The invention relates to a composition formed for promoting the tissue renewal.

No figure.